Drug intelligence / Profile preview

LCB17-0877

Development stage: Phase 2
Lead developer: LigaChem Biosciences, Inc.
Modality: Small Molecules

Overview

LCB17-0877 is a small molecule drug developed by LegoChem Biosciences (also known as LigaChem Biosciences). It functions as an autotaxin inhibitor and is currently undergoing Phase 1 clinical trials for the treatment of pulmonary fibrosis. The drug was initially licensed by LegoChem Biosciences to Bridge Biotherapeutics in 2017, and subsequently, Bridge Biotherapeutics licensed it to Boehringer Ingelheim in 2019 for further development. Boehringer Ingelheim's interest in LCB17-0877 is particularly noted as their idiopathic pulmonary fibrosis drug, Ofev, is anticipated to lose patent protection.

Targets

ENPP2 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 2)

Beyond the preview

Go deeper on LCB17-0877.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LCB17-0877.

Explore the full profile